Alpha1B adrenoceptor expression is a marker of reduced survival and increased tumor recurrence in patients with endometrioid ovarian cancer

Table 1 Distribution of adrenoceptor protein expression according to age, tumor type and tumor grade in patients with ovarian cancer

		Adrenergic receptor	Absent	Present	χ2	P
Age at diagnosis	< 49	α-1B	25 (66)	13 (34)	1.076	0.584
	50-69		55 (59)	38 (41)
	> 70		24 (54)	20 (46)
	< 49	α-2C	11 (29)	27 (71)	2.600	0.273
	50-69		38 (42)	52 (58)
	> 70		19 (45)	23 (55)
	< 49	β2	9 (31)	20 (69)	1.956	0.376
	50-69		36 (43)	47 (57)
	> 70		13 (33)	26 (67)
Tumour type	High grade serous	α-1B	49 (55)	40 (45)	14.648	0.005
	Low grade serous		4 (67)	2 (33)
	Endometrioid		25 (60)	17 (40)
	Clear cell		16 (94)	1 (6)
	Mucinous		4 (29)	10 (71)
	High grade serous	α-2C	44 (48)	47 (52)	11.038	0.026
	Low grade serous		4 (67)	2 (33)
	Endometrioid		8 (21)	31 (79)
	Clear cell		6 (35)	11 (65)
	Mucinous		5 (33)	10 (67)
	High grade serous	β2	25 (32)	54 (68)	13.559	0.009
	Low grade serous		1 (17)	5 (83)
	Endometrioid		20 (54)	17 (46)
	Clear cell		8 (61)	5 (39)
	Mucinous		1 (9)	10 (91)
Tumour grade	1	α-1B	11 (42)	15 (58)	3.472	0.176
	2		6 (55)	5 (45)
	3		81 (62)	50 (38)
	1	α-2C	9 (35)	17 (65)	0.456	0.796
	2		4 (36)	7 (64)
	3		54 (41)	77 (59)
	1	β2	4 (18)	18 (82)	4.236	0.12
	2		4 (44)	5 (56)
	3		47 (41)	68 (59)
Mortality (5 yr)	No	α-1B	55 (69)	25 (31)	4.821	0.028
	Yes		47 (52)	43 (48)
	< 5 yr	α-2C	31 (39)	48 (61)	0.001	0.969
	> 5 yr		34 (39)	52 (61)
	< 5 yr	β2	25 (36)	44 (64)	0.284	0.594
	> 5 yr		32 (41)	47 (59)

Proportion of patients showing each adrenoceptor (percentage).